Systemic immune responses to an inactivated, whole H9N2 avian influenza virus vaccine using class B CpG oligonucleotides in chickens

Singh, Shirene M.; Alkie, Tamiru Negash; Hodgins, Douglas C.; Nagy, Éva; Shojadoost, Bahram; Sharif, Shayan

doi:10.1016/j.vaccine.2015.06.043

Cited by 41 publications

(33 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccine formulations used in this study consisted of 20 μg of PLGA encapsulated AIV and 1.8–2.1 μg CpG ODN per dose in 100 μL PBS. The doses for AIV and CpG ODN were selected based on our previous work [ 15 , 38 , 39 ]. Primary vaccination was done at 7 days of age, followed by the secondary vaccination at 21 days of age.…”

Section: Methodsmentioning

confidence: 99%

“…Three consecutive passages were further conducted in the same way as in above. The presence or absence of infectious particles in allantoic fluid collected from all passages were evaluated by determining HA activity and TCID 50 in MDCK cells [ 15 ].…”

Section: Methodsmentioning

confidence: 99%

“…CpG-ODN is one of the potent vaccine adjuvants identified for increasing the efficacy of many vaccines including AIV vaccines [ 14 , 15 ]. By interacting with Toll-like receptor (TLR) 21 in chickens [ 16 ] and TLR9 in mammals [ 17 ], CpG ODN triggers innate signaling pathways, which lead to cytokine and chemokine induction, which in turn, orchestrate adaptive immunity [ 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens

et al. 2018

Self Cite

View full text Add to dashboard Cite

Mucosal vaccine delivery systems have paramount importance for the induction of mucosal antibody responses. Two studies were conducted to evaluate immunogenicity of inactivated AIV antigens encapsulated in poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles (NPs). In the first study, seven groups of specific pathogen free (SPF) layer-type chickens were immunized subcutaneously at 7-days of age with different vaccine formulations followed by booster vaccinations two weeks later. Immune responses were profiled by measuring antibody (Ab) responses in sera and lachrymal secretions of vaccinated chickens. The results indicated that inactivated AIV and CpG ODN co-encapsulated in PLGA NPs (2x NanoAI+CpG) produced higher amounts of hemagglutination inhibiting antibodies compared to a group vaccinated with non-adjuvanted AIV encapsulated in PLGA NPs (NanoAI). The tested adjuvanted NPs-based vaccine (2x NanoAI+CpG) resulted in higher IgG responses in the sera and lachrymal secretions at weeks 3, 4 and 5 post-vaccination when immunized subcutaneously. The incorporation of CpG ODN led to an increase in Ab-mediated responses and was found useful to be included both in the prime and booster vaccinations. In the second study, the ability of chitosan and mannan coated PLGA NPs that encapsulated AIV and CpG ODN was evaluated for inducing antibody responses when delivered via nasal and ocular routes in one-week-old SPF layer-type chickens. These PLGA NPs-based and surface modified formulations induced robust AIV-specific antibody responses in sera and lachrymal secretions. Chitosan coated PLGA NPs resulted in the production of large quantities of lachrymal IgA and IgG compared to mannan coated NPs, which also induced detectable amounts of IgA in addition to the induction of IgG in lachrymal secretions. In both mucosal and subcutaneous vaccination approaches, although NPs delivery enhanced Ab-mediated immunity, one booster vaccination was required to generate significant amount of Abs. These results highlight the potential of NPs-based AIV antigens for promoting the induction of both systemic and mucosal immune responses against respiratory pathogens.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Various TLR ligands have been studied for vaccine adjuvant function. Cytosine-phosphateguanine oligonucleotides (CpG ODNs) bind to TLR 21, and CpG ODN treatment has been proven to enhance vaccine immunogenicity against Salmonella Typhimurium [51], Eimeria [52], and low pathogenic avian influenza subtype H9N2 [53]. Furthermore, CpG ODN and LPS can delay the progression of Marek's disease, perhaps because of higher specific antibody response [54].…”

Section: Toll-like Receptor Ligandsmentioning

confidence: 99%

Immunomodulation of Avian Dendritic Cells under the Induction of Prebiotics

Zmrhal

Sláma

2020

Animals

View full text Add to dashboard Cite

Although the immunomodulatory properties of prebiotics were demonstrated many years ago in poultry, not all mechanisms of action are yet clear. Dendritic cells (DCs) are the main antigen-presenting cells orchestrating the immune response in the chicken gastrointestinal tract, and they are the first line of defense in the immune response. Despite the crucial role of DCs in prebiotic immunomodulatory properties, information is lacking about interaction between prebiotics and DCs in an avian model. Mannan-oligosaccharides, β-glucans, fructooligosaccharides, and chitosan-oligosaccharides are the main groups of prebiotics having immunomodulatory properties. Because pathogen-associated molecular patterns on these prebiotics are recognized by many receptors of DCs, prebiotics can mimic activation of DCs by pathogens. Short-chain fatty acids are products of prebiotic fermentation by microbiota, and their anti-inflammatory properties have also been demonstrated in DCs. This review summarizes current knowledge about avian DCs in the gastrointestinal tract, and for the first-time, their role in the immunomodulatory properties of prebiotics within an avian model.

show abstract

“…Importantly, CpG ODN stimulated both strong Th1 and B cell responses, which was similar to the immune response to IAV ( 26 ). CpG ODNs have recently been studied as IAV vaccine adjuvant in chicken ( 27 ), ducks ( 28 ), and murine models ( 29 ) delivered via the intramuscular, intradermal, and intranasal routes, respectively.…”

Section: Introductionmentioning

confidence: 99%

Topical CpG Oligodeoxynucleotide Adjuvant Enhances the Adaptive Immune Response against Influenza A Infections

et al. 2016

View full text Add to dashboard Cite

Current influenza vaccines generate humoral immunity, targeting highly variable epitopes and thus fail to achieve long-term protection. T cells recognize and respond to several highly conserved epitopes across influenza serotypes. A strategy of raising strong cytotoxic T cell memory responses to epitopes conserved across serotypes would provide cross serotype protection, eliminating the need for annual vaccination. We explored the adjuvant potential of epicutaneous (ec) and subcutaneous (sc) delivery of CpG oligodeoxynucleotide in conjunction with sc protein immunization to improve protection against influenza A virus (IAV) infections using a mouse model. We found enhanced long-term protection with epicutaneous CpG ODN (ecCpG) compared to subcutaneous CpG ODN (scCpG) as demonstrated by reduced viral titers in the lungs. This correlated with increased antigen-specific CD8 T cells in the airways and the lungs. The memory T cell response after immunization with ecCpG adjuvant was comparable to memory response by priming with IAV infection in the lungs. In addition, ecCpG was more efficient than scCpG in inducing the generation of IFN-γ producing CD4 T cells. The adjuvant effect of ecCpG was accompanied with its ability to modulate tissue-homing molecules on T cells that may direct them to the site of infection. Together, this work provides evidence for using ecCpG to induce strong antibody and memory T cell responses to confer protection against IAV infection.

show abstract

Systemic immune responses to an inactivated, whole H9N2 avian influenza virus vaccine using class B CpG oligonucleotides in chickens

Cited by 41 publications

References 27 publications

Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens

Characterization of immunogenicity of avian influenza antigens encapsulated in PLGA nanoparticles following mucosal and subcutaneous delivery in chickens

Immunomodulation of Avian Dendritic Cells under the Induction of Prebiotics

Topical CpG Oligodeoxynucleotide Adjuvant Enhances the Adaptive Immune Response against Influenza A Infections

Contact Info

Product

Resources

About